Edwards Lifesciences Corporation $EW Shares Acquired by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 186.9% during the 1st quarter, HoldingsChannel reports. The firm owned 2,941 shares of the medical research company’s stock after purchasing an additional 1,916 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Edwards Lifesciences were worth $213,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in EW. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $26,000. Vega Investment Solutions acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $27,000. SouthState Corp acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $27,000. Global X Japan Co. Ltd. lifted its holdings in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC lifted its holdings in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 205 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Finally, BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.90.

Edwards Lifesciences Stock Down 0.3%

Edwards Lifesciences stock opened at $81.01 on Thursday. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The stock’s fifty day simple moving average is $78.01 and its 200-day simple moving average is $74.88. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $47.56 billion, a P/E ratio of 11.66, a P/E/G ratio of 3.92 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company earned $0.70 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,584 shares of company stock valued at $1,897,762. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.